Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912346032> ?p ?o ?g. }
- W2912346032 endingPage "4606" @default.
- W2912346032 startingPage "4606" @default.
- W2912346032 abstract "Abstract Abstract: Background: POEMS syndrome is a constellation of symptoms of polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. Other features often present in this syndrome include papilledema, extravascular volume overload, sclerotic bone lesions, Castleman disease, high vascular endothelial growth factor (VEGF) levels and thrombocytosis/polycythemia. The standard of care has not been established in the management of the disease. We had previously reported on the role of auto-HCT in a smaller cohort of POEMS patients at our institution1. Here, we present an updated analysis in a larger cohort of POEMS patients who underwent auto-HCT. Methods: We retrospectively reviewed the outcomes of POEMS patients who underwent auto-HCT at our institution from the period of January, 1999, through June, 2018. The Kaplan-Meier method was used to caculate progression-free survival (PFS) and overall survival (OS). Hematologic response was defined as per the International Myeloma Working Group (IMWG) criteria. OS was defined as the duration from the date of transplant to death or last date of follow-up in alive patients. PFS was defined as the duration from the date of transplant to either progressive disease or death, whichever occurred first. Results: 16 patients (13 males, 3 females) with POEMS syndrome received a total of 17 auto-HCTs. One patient underwent auto-HCT two times for multiple relapses. The median age at auto-HCT was 48 years (range: 18-75). The median time from diagnosis to auto-HCT was 15 months (2-141 months). All 16 (100%) patients had peripheral neuropathy and monoclonal gammopathy: IgG lambda in 7, IgA lambda in 6, IgG kappa in 2 and light chain in 1 patient. Other features were: osteosclerotic bone lesions in 13 (81%), endocrinopathy in 10 (69%), skin involvement in 8 (50%) and extravascular fluid overload in 7 (44%). Three (18%) patients had biopsy-proven co-existent Castleman disease. Among patients with available data (n=7), the mean serum VEGF level pre-transplant was 389 pg/ml (268-1622). The median HCT-CI (comorbidity index) score available for 15 patients was 2 (range 0-7). The median number of chemotherapies received before the transplant was 1 (range 1-3). Table 1 summarizes the prior systemic chemotherapies received before auto-HCT. Two patients also received plasmapheresis, and eight patients received radiation therapy for bone disease. The mobilization regimens used for collecting peripheral blood stem cells were granulocyte colony-stimulating factor (G-CSF) alone, cyclophosphamide+G-CSF and G-CSf+plerixafor in 16, 2 and one patient, respectively. The median number of CD34+ stem cells collected was 3.43 X 106 cells/kg (range 1.73 - 6.5). The overall response rate, as per the IMWG criteria, for the entire cohort was 94% (16/17): 5 (29.4%) CR, 4 (23.5%) nCR, 1 (5.8%) VGPR, and 6 (35.2%) PR. The mean serum VEGF levels improved from 389 pg/ml before transplant to a level of 35 pg/ml (31-86) post-transplant. Engraftment syndrome was seen only in 1 patient who required corticosteroid use. One-year transplant-related mortality was 0%. Median follow-up among surviving patients is 52 months (5-120 months). The median PFS and OS have not been reached yet. All 16 patients had a complete or partial resolution of their clinical symptoms after auto-HCT. 4-year PFS and OS rate for the entire cohort is 80.2% and 100% respectively. At ten years, PFS and OS rate is 59.4% and 80% respectively. Fourteen out of 16 patients were alive at the time of the last follow-up. One patient died six years after his auto-HCT secondary to gastrointestinal bleeding unrelated to his underlying disease, and the second patient died after 11 years post auto-HCT of unknown cause. Conclusions: Upfront Auto-HCT provides durable chemotherapy free remission and significant clinical improvement in patients with POEMS syndrome. References: Patel, K. et al. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone marrow transplantation49, 465-6 (2014). Figure. Figure. Disclosures Thomas: Acerta Pharma: Research Funding; Amgen Inc: Research Funding; Bristol Myers Squibb Inc.: Research Funding; Celgene: Research Funding; Array Pharma: Research Funding. Lee:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies Corporation: Consultancy; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai Biopharmaceuticals: Consultancy; Takeda Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees. Orlowski:Poseida: Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Consultancy; Janssen Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; BioTheryX, Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millenium Pharmaceuticals: Consultancy, Research Funding. Champlin:Sanofi: Research Funding; Otsuka: Research Funding. Patel:Takeda: Research Funding; Poseida Therapeutics, Inc.: Research Funding; Abbvie: Research Funding; Celgene: Research Funding." @default.
- W2912346032 created "2019-02-21" @default.
- W2912346032 creator A5001940718 @default.
- W2912346032 creator A5008785159 @default.
- W2912346032 creator A5015342719 @default.
- W2912346032 creator A5016928938 @default.
- W2912346032 creator A5017057018 @default.
- W2912346032 creator A5024842091 @default.
- W2912346032 creator A5029237145 @default.
- W2912346032 creator A5037077714 @default.
- W2912346032 creator A5037240227 @default.
- W2912346032 creator A5038235561 @default.
- W2912346032 creator A5045900095 @default.
- W2912346032 creator A5048362577 @default.
- W2912346032 creator A5048913229 @default.
- W2912346032 creator A5050962913 @default.
- W2912346032 creator A5055929208 @default.
- W2912346032 creator A5059394802 @default.
- W2912346032 creator A5060313982 @default.
- W2912346032 creator A5066894053 @default.
- W2912346032 creator A5068834306 @default.
- W2912346032 creator A5069460930 @default.
- W2912346032 date "2018-11-29" @default.
- W2912346032 modified "2023-09-28" @default.
- W2912346032 title "Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome" @default.
- W2912346032 doi "https://doi.org/10.1182/blood-2018-99-115710" @default.
- W2912346032 hasPublicationYear "2018" @default.
- W2912346032 type Work @default.
- W2912346032 sameAs 2912346032 @default.
- W2912346032 citedByCount "0" @default.
- W2912346032 crossrefType "journal-article" @default.
- W2912346032 hasAuthorship W2912346032A5001940718 @default.
- W2912346032 hasAuthorship W2912346032A5008785159 @default.
- W2912346032 hasAuthorship W2912346032A5015342719 @default.
- W2912346032 hasAuthorship W2912346032A5016928938 @default.
- W2912346032 hasAuthorship W2912346032A5017057018 @default.
- W2912346032 hasAuthorship W2912346032A5024842091 @default.
- W2912346032 hasAuthorship W2912346032A5029237145 @default.
- W2912346032 hasAuthorship W2912346032A5037077714 @default.
- W2912346032 hasAuthorship W2912346032A5037240227 @default.
- W2912346032 hasAuthorship W2912346032A5038235561 @default.
- W2912346032 hasAuthorship W2912346032A5045900095 @default.
- W2912346032 hasAuthorship W2912346032A5048362577 @default.
- W2912346032 hasAuthorship W2912346032A5048913229 @default.
- W2912346032 hasAuthorship W2912346032A5050962913 @default.
- W2912346032 hasAuthorship W2912346032A5055929208 @default.
- W2912346032 hasAuthorship W2912346032A5059394802 @default.
- W2912346032 hasAuthorship W2912346032A5060313982 @default.
- W2912346032 hasAuthorship W2912346032A5066894053 @default.
- W2912346032 hasAuthorship W2912346032A5068834306 @default.
- W2912346032 hasAuthorship W2912346032A5069460930 @default.
- W2912346032 hasConcept C126322002 @default.
- W2912346032 hasConcept C141071460 @default.
- W2912346032 hasConcept C159654299 @default.
- W2912346032 hasConcept C203014093 @default.
- W2912346032 hasConcept C2775892965 @default.
- W2912346032 hasConcept C2776210965 @default.
- W2912346032 hasConcept C2776364478 @default.
- W2912346032 hasConcept C2778551932 @default.
- W2912346032 hasConcept C2779788118 @default.
- W2912346032 hasConcept C2780411336 @default.
- W2912346032 hasConcept C2911091166 @default.
- W2912346032 hasConcept C36394416 @default.
- W2912346032 hasConcept C71924100 @default.
- W2912346032 hasConcept C72563966 @default.
- W2912346032 hasConcept C89560881 @default.
- W2912346032 hasConceptScore W2912346032C126322002 @default.
- W2912346032 hasConceptScore W2912346032C141071460 @default.
- W2912346032 hasConceptScore W2912346032C159654299 @default.
- W2912346032 hasConceptScore W2912346032C203014093 @default.
- W2912346032 hasConceptScore W2912346032C2775892965 @default.
- W2912346032 hasConceptScore W2912346032C2776210965 @default.
- W2912346032 hasConceptScore W2912346032C2776364478 @default.
- W2912346032 hasConceptScore W2912346032C2778551932 @default.
- W2912346032 hasConceptScore W2912346032C2779788118 @default.
- W2912346032 hasConceptScore W2912346032C2780411336 @default.
- W2912346032 hasConceptScore W2912346032C2911091166 @default.
- W2912346032 hasConceptScore W2912346032C36394416 @default.
- W2912346032 hasConceptScore W2912346032C71924100 @default.
- W2912346032 hasConceptScore W2912346032C72563966 @default.
- W2912346032 hasConceptScore W2912346032C89560881 @default.
- W2912346032 hasIssue "Supplement 1" @default.
- W2912346032 hasLocation W29123460321 @default.
- W2912346032 hasOpenAccess W2912346032 @default.
- W2912346032 hasPrimaryLocation W29123460321 @default.
- W2912346032 hasRelatedWork W2596994951 @default.
- W2912346032 hasRelatedWork W2770915372 @default.
- W2912346032 hasRelatedWork W2906892128 @default.
- W2912346032 hasRelatedWork W2953802173 @default.
- W2912346032 hasRelatedWork W3012440518 @default.
- W2912346032 hasRelatedWork W3166769650 @default.
- W2912346032 hasRelatedWork W3191440482 @default.
- W2912346032 hasRelatedWork W35539717 @default.
- W2912346032 hasRelatedWork W4205127079 @default.
- W2912346032 hasRelatedWork W4233223391 @default.
- W2912346032 hasVolume "132" @default.
- W2912346032 isParatext "false" @default.
- W2912346032 isRetracted "false" @default.